Clinical Trials Search

Titlesort descending Intervention NCT ID Sponsor Status
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and... Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Ondansetron Hydrochloride, Palonosetron Hydrochloride, Placebo NCT03578081 Alliance for Clinical Trials in Oncology Recruiting
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2... Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment NCT03633331 Alliance for Clinical Trials in Oncology Active, not recruiting
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil Donepezil 5 mg, Placebo NCT02822573 Wake Forest University Health Sciences Recruiting
Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk Metformin, Placebo NCT02028221 University of Arizona Active, not recruiting
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Questionnaire Administration, Placebo Administration, Endoxifen Hydrochloride NCT03317405 National Cancer Institute (NCI) Active, not recruiting
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-... Denosumab, Salpingo-Oophorectomy NCT03382574 National Cancer Institute (NCI) Recruiting
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast... Endocrine therapy interruption NCT02308085 International Breast Cancer Study Group Active, not recruiting
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation Pamidronate, Calcium and vitamin D NCT02074631 Masonic Cancer Center, University of Minnesota Recruiting
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine NCT03036930 National Cancer Institute (NCI) Active, not recruiting
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer... Laboratory Biomarker Analysis, Rilimogene Galvacirepvec, Placebo Administration NCT02326805 National Cancer Institute (NCI) Active, not recruiting

Pages